title: Medically refractory neurosarcoidosis treated with infliximab.
abstract: Neurosarcoidosis can worsen despite standard immunosuppressive therapy, a situation for which there is no established medical management. We present three cases of medically refractory neurosarcoidosis treated with infliximab. All three patients showed a clinical response to this treatment and side effects were limited. A summary of reported cases of neurosarcoidosis treated with infliximab is included. This case series supports a role for infliximab in the treatment of patients with medically refractory neurosarcoidosis.
authors.affiliation: Department of Medicine, University of Auckland Department of Neurology, Auckland City Hospital, Auckland, New Zealand. j.pereira@auckland.ac.nz
authors.forename: J
authors.initials: J
authors.lastname: Pereira
authors.forename: N E
authors.initials: NE
authors.lastname: Anderson
authors.forename: D
authors.initials: D
authors.lastname: McAuley
authors.forename: P
authors.initials: P
authors.lastname: Bergin
authors.forename: D
authors.initials: D
authors.lastname: Kilfoyle
authors.forename: J
authors.initials: J
authors.lastname: Fink
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002493:Central Nervous System Diseases / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology; D004334:Drug Administration Schedule; D004351:Drug Resistance / Q000187:drug effects / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D000069285:Infliximab; D008297:Male; D012507:Sarcoidosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab